Volume | 42 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aditxt Inc | ADTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.04 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
5 | 42 | - | 2.95 - 76.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:44:15 | 1 | $ 3.00 | USD |
Aditxt Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.06M | 1.67M | - | 934k | -27.65M | -16.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aditxt News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.17 | 3.2399 | 2.95 | 3.08 | 22,910 | -0.13 | -4.10% |
1 Month | 3.52 | 4.10 | 2.95 | 3.73 | 97,905 | -0.48 | -13.64% |
3 Months | 5.23 | 6.34 | 2.95 | 4.34 | 120,361 | -2.19 | -41.87% |
6 Months | 13.33 | 24.00 | 2.95 | 5.93 | 724,173 | -10.29 | -77.19% |
1 Year | 35.60 | 76.40 | 2.95 | 16.92 | 668,410 | -32.56 | -91.46% |
3 Years | 113.20 | 1,139.60 | 2.95 | 49.64 | 2,252,934 | -110.16 | -97.31% |
5 Years | 211.20 | 1,139.60 | 2.95 | 73.17 | 2,239,923 | -208.16 | -98.56% |
Aditxt Description
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |